These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 17393066)

  • 1. Astrocytic activation in relation to inflammatory markers during clinical exacerbation of relapsing-remitting multiple sclerosis.
    Rejdak K; Petzold A; Kocki T; Kurzepa J; Grieb P; Turski WA; Stelmasiak Z
    J Neural Transm (Vienna); 2007; 114(8):1011-5. PubMed ID: 17393066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis.
    Rejdak K; Petzold A; Stelmasiak Z; Giovannoni G
    Mult Scler; 2008 Jan; 14(1):59-66. PubMed ID: 17893112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations.
    Petzold A; Eikelenboom MJ; Gveric D; Keir G; Chapman M; Lazeron RH; Cuzner ML; Polman CH; Uitdehaag BM; Thompson EJ; Giovannoni G
    Brain; 2002 Jul; 125(Pt 7):1462-73. PubMed ID: 12076997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis.
    Rejdak K; Eikelenboom MJ; Petzold A; Thompson EJ; Stelmasiak Z; Lazeron RH; Barkhof F; Polman CH; Uitdehaag BM; Giovannoni G
    Neurology; 2004 Oct; 63(8):1439-45. PubMed ID: 15505162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis.
    Petzold A; Brassat D; Mas P; Rejdak K; Keir G; Giovannoni G; Thompson EJ; Clanet M
    Mult Scler; 2004 Jun; 10(3):281-3. PubMed ID: 15222692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum and cerebrospinal fluid nitrite and nitrate levels in relapsing-remitting and secondary progressive multiple sclerosis patients.
    Yuceyar N; Taşkiran D; Sağduyu A
    Clin Neurol Neurosurg; 2001 Dec; 103(4):206-11. PubMed ID: 11714562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S100B as a Potential Biomarker and Therapeutic Target in Multiple Sclerosis.
    Barateiro A; Afonso V; Santos G; Cerqueira JJ; Brites D; van Horssen J; Fernandes A
    Mol Neurobiol; 2016 Aug; 53(6):3976-3991. PubMed ID: 26184632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients.
    Rejdak K; Bartosik-Psujek H; Dobosz B; Kocki T; Grieb P; Giovannoni G; Turski WA; Stelmasiak Z
    Neurosci Lett; 2002 Oct; 331(1):63-5. PubMed ID: 12359324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of neuroactive steroids in cerebrospinal fluid comparing acute relapse and stable disease in relapsing-remitting multiple sclerosis.
    Orefice N; Carotenuto A; Mangone G; Bues B; Rehm R; Cerillo I; Saccà F; Calignano A; Orefice G
    J Steroid Biochem Mol Biol; 2016 May; 159():1-7. PubMed ID: 26892094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study.
    Takano R; Misu T; Takahashi T; Sato S; Fujihara K; Itoyama Y
    Neurology; 2010 Jul; 75(3):208-16. PubMed ID: 20644148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum and cerebrospinal fluid concentrations of homoarginine, arginine, asymmetric and symmetric dimethylarginine, nitrite and nitrate in patients with multiple sclerosis and neuromyelitis optica.
    Haghikia A; Kayacelebi AA; Beckmann B; Hanff E; Gold R; Haghikia A; Tsikas D
    Amino Acids; 2015 Sep; 47(9):1837-45. PubMed ID: 26055922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Some markers of neuronal damage in cerebrospinal fluid of multiple sclerosis patients in relapse.
    Mitosek-Szewczyk K; Gordon-Krajcer W; Flis D; Stelmasiak Z
    Folia Neuropathol; 2011; 49(3):191-6. PubMed ID: 22101952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum and cerebrospinal fluid S100B, neuron-specific enolase, and total tau protein in acute encephalopathy with biphasic seizures and late reduced diffusion: a diagnostic validity.
    Shiihara T; Miyake T; Izumi S; Watanabe M; Kamayachi K; Kodama K; Nabetani M; Ikemiyagi M; Yamaguchi Y; Sawaura N
    Pediatr Int; 2012 Feb; 54(1):52-5. PubMed ID: 21883688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosis.
    Bartosik-Psujek H; Stelmasiak Z
    J Neural Transm (Vienna); 2006 Mar; 113(3):339-45. PubMed ID: 15997419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS.
    Malmeström C; Haghighi S; Rosengren L; Andersen O; Lycke J
    Neurology; 2003 Dec; 61(12):1720-5. PubMed ID: 14694036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raised cerebrospinal fluid nitrite and nitrate levels in patients with multiple sclerosis: no correlation with disease activity.
    Drulović J; Dujmović I; Mesaros S; Samardzić T; Maksimović D; Stojsavljević N; Lević Z; Mostarica Stojokvić M
    Mult Scler; 2001 Feb; 7(1):19-22. PubMed ID: 11321188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis.
    Brettschneider J; Petzold A; Junker A; Tumani H
    Mult Scler; 2006 Apr; 12(2):143-8. PubMed ID: 16629417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipopolysaccharide modulates astrocytic S100B secretion: a study in cerebrospinal fluid and astrocyte cultures from rats.
    Guerra MC; Tortorelli LS; Galland F; Da Ré C; Negri E; Engelke DS; Rodrigues L; Leite MC; Gonçalves CA
    J Neuroinflammation; 2011 Oct; 8():128. PubMed ID: 21970823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis.
    Guimarães I; Cardoso MI; Sá MJ
    Mult Scler; 2006 Jun; 12(3):354-6. PubMed ID: 16764350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid from patients with neurodegenerative and neuroinflammatory diseases: no evidence for rat glial activation in vitro.
    Wilms H; Rosenstiel P; Sievers J; Deuschl G; Lucius R
    Neurosci Lett; 2001 Nov; 314(3):107-10. PubMed ID: 11704295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.